Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$7.54 USD
+0.05 (0.67%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $7.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Cash flow Statements
Fiscal Year End for Emergent Biosolutions Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -760.50 | -223.80 | 230.90 | 305.10 | 54.50 |
Depreciation/Amortization & Depletion | 364.60 | 147.40 | 127.90 | 118.00 | 113.70 |
Net Change from Assets/Liabilities | -75.10 | 0.50 | -124.60 | -2.40 | -42.40 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 264.70 | 41.80 | 86.90 | 115.30 | 62.20 |
Net Cash From Operating Activities | -206.30 | -34.10 | 321.10 | 536.00 | 188.00 |
Property & Equipment | -51.60 | -115.80 | -225.00 | -141.00 | -86.90 |
Acquisition/ Disposition of Subsidiaries | 270.20 | -243.70 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | -6.30 | -21.80 | 0.00 | -10.00 | -10.00 |
Net Cash from Investing Activities | 212.30 | -381.30 | -225.00 | -151.00 | -96.90 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | -82.10 | -106.00 | 0.00 | 8.20 |
Issuance (Repayment) of Debt | -543.40 | 564.20 | -35.90 | 62.90 | 13.70 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 7.70 | -0.90 | 0.90 | 6.60 | -57.80 |
Net Cash from Financing Activities | -535.70 | 481.20 | -141.00 | 69.50 | -35.90 |
Effect of Exchange Rate Changes | -1.20 | 0.50 | -0.30 | -1.00 | 0.40 |
Net Change In Cash & Equivalents | -530.90 | 66.30 | -45.20 | 453.50 | 55.60 |
Cash at Beginning of Period | 642.60 | 576.30 | 621.50 | 168.00 | 112.40 |
Cash at End of Period | 111.70 | 642.60 | 576.30 | 621.50 | 168.00 |
Diluted Net EPS | -14.85 | -4.47 | 4.27 | 5.67 | 1.04 |
Fiscal Year End for Emergent Biosolutions Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 9.00 | -760.50 | -711.00 | -444.30 | -183.00 |
Depreciation/Amortization & Depletion | 34.80 | 364.60 | 329.30 | 77.40 | 35.60 |
Net Change from Assets/Liabilities | -98.70 | -75.10 | -116.80 | -196.20 | -28.40 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -7.70 | 264.70 | 260.10 | 264.70 | -8.20 |
Net Cash From Operating Activities | -62.60 | -206.30 | -238.40 | -298.40 | -184.00 |
Property & Equipment | -10.80 | -51.60 | -40.20 | -27.60 | -15.10 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 270.20 | 270.20 | 270.20 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | -6.30 | -6.30 | 0.00 | 0.00 |
Net Cash from Investing Activities | -10.80 | 212.30 | 223.70 | 242.60 | -15.10 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | 41.10 | -543.40 | -547.50 | -504.60 | -8.40 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.40 | 7.70 | 7.10 | 7.20 | -2.10 |
Net Cash from Financing Activities | 40.70 | -535.70 | -540.40 | -497.40 | -10.50 |
Effect of Exchange Rate Changes | 0.00 | -1.20 | 0.30 | -0.80 | -2.80 |
Net Change In Cash & Equivalents | -32.70 | -530.90 | -554.80 | -554.00 | -212.40 |
Cash at Beginning of Period | 111.70 | 642.60 | 642.60 | 642.60 | 642.60 |
Cash at End of Period | 79.00 | 111.70 | 87.80 | 88.60 | 430.20 |
Diluted Net EPS | 0.17 | -0.97 | -5.08 | -5.15 | -3.65 |